http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24823151

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't
endingPage 36
issn 1532-1827
0007-0920
issueIdentifier 1
pageRange 28-36
publicationName British Journal of Cancer
startingPage 28
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_916de93fe8f49855f42e16db43537393
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_e01c0ffaf1fdbea232a88aa8b5bc8669
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_d6fb759f3be57da862ee8958d1d118b9
bibliographicCitation Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A. A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. British Journal of Cancer. 2009 Jan 06;100(1):28–36. doi: 10.1038/sj.bjc.6604817.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b1bf2b5d2a231e17cb7692fa4650525
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53f33294171f5f3caa1e179df70a8995
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8c8b665d62ebd4020c5f31e5f03d7b2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a52cdae836b0ff816dd7aa59d0094082
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75f1a66d0cbbb7d52f51b0c36cc72051
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c24ded9995219492e90331bae59602e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6ce690d19b7eed33f08465acc5418e85
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d43a40495ab471a4f68d2b860e62460
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1383f7fad0a713e06d6c0bf3093c8ae
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_afc4c12f526a151d119b61b229238cce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b42956042966677dd67f34bcbb8ea46e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2bcce7c7514aec1bedb2f899c614267d
date 2009-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1038/sj.bjc.6604817
https://pubmed.ncbi.nlm.nih.gov/19127265
https://pubmed.ncbi.nlm.nih.gov/PMC2634690
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765
https://portal.issn.org/resource/ISSN/0007-0920
https://portal.issn.org/resource/ISSN/1532-1827
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/
title A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
discusses http://id.nlm.nih.gov/mesh/M0007520
http://id.nlm.nih.gov/mesh/M0022501
http://id.nlm.nih.gov/mesh/M0527853
http://id.nlm.nih.gov/mesh/M0005636
http://id.nlm.nih.gov/mesh/M0025711
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2942
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3121
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.5.1.98
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3549980
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16760703
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398738

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245921350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129552408
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136090536
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127830723
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127838758
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247375212
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129095671
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128706830

Total number of triples: 59.